Company intelligence / Profile preview
Aegle Therapeutics
Miami, Florida, United Statesaegletherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Aegle Therapeutics is currently conducting Phase 1/2a clinical trials for AGLE-102 in patients with Dystrophic Epidermolysis Bullosa (DEB) and severe burns. The first patient in the DEB trial was dosed in August 2024. The company has reported compelling clinical results in burns.
- Therapeutic areas
- ImmunologyRare DiseasesDermatology
- Modalities
- Extracellular vesicle (EV) therapyMesenchymal stem cell-derived extracellular vesicles
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Aegle Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aegle Therapeutics.